相关实验视频

Updated: Jul 28, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

在移植后的侵袭性B细胞淋巴瘤中,瘤微环境的表征和临床影响

Suvi-Katri Leivonen¹, Terhi Friman², Matias Autio¹

¹Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.

|June 1, 2023

概括

移植后的攻击性B细胞淋巴瘤 (PT-ABCL) 显示出不同的瘤微环境. 一个炎症的微环境,富含免疫细胞和与EBV相关,预测移植患者的更好的结果.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
移植移植移植移植

背景情况:

移植后淋巴增殖性疾病 (PTLD) 是由移植受体免疫抑制引起的淋巴细胞增殖.
PTLD,特别是攻击性B细胞淋巴瘤 (PT-ABCL),表现出不同的临床行为.
了解瘤微环境 (TME) 对于预测PT-ABCL结果至关重要.

研究的目的:

为了全面描述PT-ABCL中的TME.
为了确定与爱斯坦-巴尔病毒 (EBV) 状态和患者预后相关的TME特征.
为了比较PT-ABCL和免疫能力扩散的大B细胞淋巴瘤之间的TME特征.

主要方法:

在75个PT-ABCL样本中对700多个TME相关基因的基因表达概况.
在的免疫类型定型以确定免疫细胞的组成.
多变量分析包括EBV状态,国际预后指数和治疗.

主要成果:

具有EBV阳性的PT-ABCL被丰富为I型干扰素和抗病毒反应基因.
一个细胞毒性基因特征与EBV阳性相关,并改善了整体存活率 (OS).
一个具有较高免疫细胞透率的"炎症"TME亚组显示出明显更好的OS (>200.0 vs. 15.2个月).
炎症性TME是有利结果的独立预测因素,即使在调整其他预后因素后也是如此.
与免疫能力相比,PT-扩散大B细胞淋巴瘤的T细胞比例较低.

结论:

TME的免疫细胞组成是PT-ABCL临床行为和预后的关键决定因素.
EBV状态影响TME基因表达,并与有利的结果有关.
针对或理解TME可能为PT-ABCL提供新的治疗策略.

更多相关视频

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.